Henry J. Fuchs, M.D.

Henry J. Fuchs, M.D.

Former President, Worldwide Research & DevelopmentatBiomarin Pharmaceutical· In proxies 2021–2024

Pay in FY2024-16% from the year before · Biomarin Pharmaceutical stock -31.8% the same year

Henry J. Fuchs, M.D. was paid $8.1M in FY2024 (Dec), down 16%. Biomarin Pharmaceutical stock fell 31.8% that year.

Pay$100 in the stock at the end of FY20 → $75
Pay is from the Summary Compensation Table of each Biomarin Pharmaceutical proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Biomarin PharmaceuticalPublic company · 5 yr
    • Former President, Worldwide Research & Development2021 – Present · 5 yrStock in role -37%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?